Retrospective Evaluation of Cutaneous Malignant Melanoma Patients in the Eastern Black Sea Region in Terms of Tumor Thickness and Survival: Cohort Study

4%) were found to be alive. 88% of the patients were still alive at the end of the first year after diagnosis, 75% at the end of the 2nd year, and 48% at the end of the 5th year. At the end of 5 years, 57% of the patients with Breslow thickness ≤ 4 mm were still alive, while 39% of the patients with >4 mm were still alive. Conclusion: Unlike studies abroad, malignant melanoma in our country diagnosis is delayed. Early diagnosis modalities should be developed to achieve better survival rates.